{"name":"Wockhardt","slug":"wockhardt","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Cefepime-zidebactam (FEP-ZID)","genericName":"Cefepime-zidebactam (FEP-ZID)","slug":"cefepime-zidebactam-fep-zid","indication":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","status":"phase_3"},{"name":"Intravenous Levonadifloxacin/Linezolid Infusion","genericName":"Intravenous Levonadifloxacin/Linezolid Infusion","slug":"intravenous-levonadifloxacin-linezolid-infusion","indication":"Complicated skin and soft tissue infections","status":"phase_3"},{"name":"Oral Levonadifloxacin/Linezolid Tablet","genericName":"Oral Levonadifloxacin/Linezolid Tablet","slug":"oral-levonadifloxacin-linezolid-tablet","indication":"Bacterial infections (specific indications in Phase 3 development not publicly detailed)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cefepime 2000 mg","genericName":"Cefepime 2000 mg","slug":"cefepime-2000-mg","indication":"Other","status":"marketed"},{"name":"FEP-ZID","genericName":"FEP-ZID","slug":"fep-zid","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Novolin 70/30","genericName":"Novolin 70/30","slug":"novolin-70-30","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Novolin N","genericName":"Novolin N","slug":"novolin-n","indication":"Type 1 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Cefepime 2000 mg","genericName":"Cefepime 2000 mg","slug":"cefepime-2000-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cefepime-zidebactam (FEP-ZID)","genericName":"Cefepime-zidebactam (FEP-ZID)","slug":"cefepime-zidebactam-fep-zid","phase":"phase_3","mechanism":"Cefepime-zidebactam is a combination of a fourth-generation cephalosporin (cefepime) and a novel beta-lactamase inhibitor (zidebactam) that together restore cefepime's activity against beta-lactamase-producing gram-negative bacteria.","indications":["Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)","Complicated intra-abdominal infections (cIAI)"],"catalyst":""},{"name":"FEP-ZID","genericName":"FEP-ZID","slug":"fep-zid","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Intravenous Levonadifloxacin/Linezolid Infusion","genericName":"Intravenous Levonadifloxacin/Linezolid Infusion","slug":"intravenous-levonadifloxacin-linezolid-infusion","phase":"phase_3","mechanism":"This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria.","indications":["Complicated skin and soft tissue infections","Hospital-acquired pneumonia","Community-acquired pneumonia with resistant pathogens"],"catalyst":""},{"name":"Novolin 70/30","genericName":"Novolin 70/30","slug":"novolin-70-30","phase":"marketed","mechanism":"Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Novolin N","genericName":"Novolin N","slug":"novolin-n","phase":"marketed","mechanism":"Novolin N is an intermediate-acting insulin that binds to insulin receptors on cells to facilitate glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Oral Levonadifloxacin/Linezolid Tablet","genericName":"Oral Levonadifloxacin/Linezolid Tablet","slug":"oral-levonadifloxacin-linezolid-tablet","phase":"phase_3","mechanism":"This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria.","indications":["Bacterial infections (specific indications in Phase 3 development not publicly detailed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"pipeline","source":"Business Standard","summary":"Wockhardt Ltd spurts 3.61%, rises for fifth straight session - Business Standard","headline":"Wockhardt Ltd spurts 3.61%, rises for fifth straight session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNVklzTTA4eDdxbnEyN0lSY2pqTHd2QUphSjNqSm5XZzdBNGpfS3h6NGFBTHdZRDFza29kVmI1MmdyQnc1S1VJdjlfNC1pLXZLSUVhRk92RjViNzYxbkp1N0EtSUpNYzdwOGZjdmJkWkRiajdZZzVxRmVXd3htZXVmMTRDX2hXTUNyVXp2WnlCTVRBSzFyWm5nZ2F6bTRFSUZCN1dEbUZzaGlieldYM3FWam1tR2F6S0dqYmhyYVlKbzhkOUU5d0xHaWtDc2pDZEhXOUtoREd1cE5HQnEtazlLZFpIWEYxWHk2NklOVnpTZjFta3ZzMkxDNzdKaGFvMkZKN3FFcWx6R0N3WkU4d3Vad1N2VmxzX29FWW13WUZVT0MwZGktWGlWbGVQblZLanczajBDaTYwT08xYXM3b2JJbVVlWEd3bS1mN3VSbXluSmhuYUFoVUE?oc=5","date":"2026-04-06","type":"pipeline","source":"msn.com","summary":"Wockhardt Rebounds From Friday's Slump; Stock Surges 9% — Here's Why - msn.com","headline":"Wockhardt Rebounds From Friday's Slump; Stock Surges 9% — Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNOUFmTDRES0VESWVGOW5qQ0dGRUpmTzY1MHNWeW5FVjctTUdCVDFDcUM4M19nVmlyTnoySE9tOHJTalhlQWJHT1NsNmVxak12RTJqUjVNNzdpcWRvR1R1bmt0ZzJRbEpMZWVKX1ltYmEzS3htZmJ4bXlPSUwzcWlOaVV4bkpGTTluejlOQlVfMWEyYWRNdng2T2RjblA5eTZoZENqNmtzeXlCZHF1Ymw0eV82UTF0WjMyMzIyTWdB?oc=5","date":"2026-04-06","type":"pipeline","source":"Markets Mojo","summary":"Wockhardt Ltd Valuation Shifts Signal Changing Market Sentiment - Markets Mojo","headline":"Wockhardt Ltd Valuation Shifts Signal Changing Market Sentiment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1wRjIzZjN3enQ4QVJvSDJXOWRaSXZ0U2FlSzdXVGdLWVVsSlk0UlR0SklvcUdlTW5VQllLcVFRUTJLZ1JsbUUxR0JRRWR1a3BLWEhZYVozdGhqdnVKX3FKMF9SZlZoLTNRRVgwOWd4R0M?oc=5","date":"2026-04-05","type":"pipeline","source":"Fathom Journal","summary":"Bajaj Finance, Shriram Finance, Belrise और Wockhardt में क्या करें? | Top Gainers & Losers Analysis [d3a850] - Fathom Journal","headline":"Bajaj Finance, Shriram Finance, Belrise और Wockhardt में क्या करें? | Top Gainers & Losers Analysis [d3a850]","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-08","type":"pipeline","source":"Medical Dialogues","summary":"Wockhardt's Nafithromycin 400 mg May Get 5-Year Price Control Exemption - Medical Dialogues","headline":"Wockhardt's Nafithromycin 400 mg May Get 5-Year Price Control Exemption","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-31","type":"pipeline","source":"simplywall.st","summary":"Investing in Wockhardt (NSE:WOCKPHARMA) three years ago would have delivered you a 611% gain - simplywall.st","headline":"Investing in Wockhardt (NSE:WOCKPHARMA) three years ago would have delivered you a 611% gain","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-03","type":"pipeline","source":"simplywall.st","summary":"While individual investors own 34% of Wockhardt Limited (NSE:WOCKPHARMA), private companies are its largest shareholders with 50% ownership - simplywall.st","headline":"While individual investors own 34% of Wockhardt Limited (NSE:WOCKPHARMA), private companies are its largest shareholders","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-01","type":"regulatory","source":"The Times of India","summary":"Wockhardt jumps over 19% after USFDA accepts its new drug filing - The Times of India","headline":"Wockhardt jumps over 19% after USFDA accepts its new drug filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMi1kLXhpWlo1UGhNVzRURWVxZ1lfa1p2ZmwwUDNldk9WS3BKUU1kQjVRVlVONXNhVUt1d2NVazM4QmJXOXFadEJZRkRPYmVud0VCWWVGRld5WXRaakZXTjZvZFRwU0VyT0taWTJyZzdmUjhZUXpFQkduMWd5RDdWNVhhS1RxWXd3M1I3R2dnNVE0b2VydDJ0YVpTaFpDaGJuNTF0bjZRcmk?oc=5","date":"2025-12-01","type":"regulatory","source":"HDFC Sky","summary":"Wockhardt Share Price Surge 18% as US FDA Accepts NDA for Zaynich - HDFC Sky","headline":"Wockhardt Share Price Surge 18% as US FDA Accepts NDA for Zaynich","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQM2RKRElmQUlWZmZVYVA5TDdCcTEyRWhLMVZHMnpMWDNDdGR3N2F6YUltYkVSQ0RJTWNMVEdmalEtUFR6YjVrTVpxcU1ndnVUSlF5UWlrajRDRDRuV3d3QWNZTEdGeWszbzhuak0yYUoxRm1Qd0pnVjVkT0RnTERhWlpCTUl0aWJSX1RUMWp5UHFGSW5GTlFYc2tHVWNRcVJJcjQ0QzlJVHFCYjBEenp1Zlk0aHAwM2U3QWN0eVcxb1JrUXZ4YWgtcmVlYkZZcGh4TVBuQVlQaVFrVjl6ZzkxR20yTUpzQThBMU5yZEdOdVV5N3AwSUgtejJ2c3RCQnAyUUk0cGF3T0tRTy1DbWlsamdzSndrOEHSAZwCQVVfeXFMT1hwNjlYRW55a01yTko3RWxJWjJFSEFJaWl0Rnp2VUxVcW9ZY2thN1hBRmkwRkdFMmZDLURFOHoxOUszNmwzRk5zMnlia2YtWTZVRFd3eVRnWmtZUHNqMWFrYTg0dGNMRDdFMDRNMTB0WG5OdUVHWmMwZm16VHppWFFqc1d0al9zMWVEV3BOczVMRkZkcmpTTHluU05OVlJRY20xWi1tS0x6elpTSzhPRTRqNUtZN3hBbGRBd210UmZoNUVkX0piVFNlYlJkVVJXdmxHcXdGR210QjJfXzRmeWlnMVRQTkFteXNBS1FrQ2cyQmtxcE5vTFFNSkRkckpmMkVXaVc4VktnQ3lqUy0tTnczamkwQXBKQ0Z2bU4?oc=5","date":"2025-07-11","type":"patent","source":"The Economic Times","summary":"Wockhardt Ltd dumps US generic pharma segment after losses, bets on antibiotics and insulin - The Economic Times","headline":"Wockhardt Ltd dumps US generic pharma segment after losses, bets on antibiotics and insulin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNeWs1STlRcXRyWHdyRG9aVXVRYzJiTEl5S0RJWUtYWUMzcVRVZHdCSHktVHk3VzZ1c05rZ0lHSlpxcFFSRUtzQjhIUjdSdGZqemJIRTFlZnZPdl9HQ1p3QXNxdU9uMHFpRzE5eTBBME5iTFlQcC1GbFRhc0E5X1ptLTQ0MGU2M2RaOVRaSTMzZjVZQ2dvWGVsaW1oTnJEMzQ5SlNoaHA2NlluNDc50gGzAUFVX3lxTE95TTZvb1BwUGNYWjVVdkNZUFI5Q3dVclY5U210ejVJWlRnZVRVci1uQjVQQ0owSVo0ZElmTjZidWJwTmM4bmZFck9kemVVVWRXa041NHE5SmxnTHZWSWI5cDllNm00cnkwWnVNVGticmEtd3YtNjV6ajJzS2N6Skd2bHBubmlFb1drOEsyNjF5Ym9iTTk0d05hV2tzSnczNXJfSzBCS2RzT3lPOG1aZnlzN3Fv?oc=5","date":"2025-07-11","type":"patent","source":"The Indian Express","summary":"Wockhardt to exit US generic pharma segment, shut down 2 subsidiaries - The Indian Express","headline":"Wockhardt to exit US generic pharma segment, shut down 2 subsidiaries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQYWI5THh3UWR4YW9nSDNrQ1RiRDVjNld3WmpLeE1YdGNwREVYbFhGT2xjaklpQ1VpNGs0Q3NsS1VnMWgxa2Fmc1BLemxjUmJQOFFESDJLMmh2U2FURkZMaWtaYXdDOW5TNUlCUXp1UTNsQjVBT2JnWkV2MkJxWEVoek1nMkpvdw?oc=5","date":"2025-06-06","type":"pipeline","source":"pharmaphorum","summary":"Wockhardt has high hopes for novel antibiotic Zaynich - pharmaphorum","headline":"Wockhardt has high hopes for novel antibiotic Zaynich","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":3,"phase_3":3,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}